Elpida®
Sponsors
Viriom
Conditions
HIV-1-infectionHepatic Impairment
Phase 1
Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects
CompletedNCT03706924
Start: 2018-06-01End: 2018-10-12Updated: 2018-10-30
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
CompletedNCT03706898
Start: 2018-10-01End: 2019-04-10Updated: 2022-01-11
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
CompletedNCT03709355
Start: 2018-11-14End: 2019-09-06Updated: 2022-01-26
Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®
CompletedNCT05163535
Start: 2021-01-19End: 2021-08-03Updated: 2022-01-11